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No evidence for basigin/CD147 
as a direct SARS‑CoV‑2 spike 
binding receptor
Jarrod Shilts 1*, Thomas W. M. Crozier 2, Edward J. D. Greenwood2, Paul J. Lehner 2 & 
Gavin J. Wright 1,3*
The spike protein of SARS‑CoV‑2 is known to enable viral invasion into human cells through direct 
binding to host receptors including ACE2. An alternate entry receptor for the virus was recently 
proposed to be basigin/CD147. These early studies have already prompted a clinical trial and multiple 
published hypotheses speculating on the role of this host receptor in viral infection and pathogenesis. 
Here, we report that we are unable to find evidence supporting the role of basigin as a putative 
spike binding receptor. Recombinant forms of the SARS‑CoV‑2 spike do not interact with basigin 
expressed on the surface of human cells, and by using specialized assays tailored to detect receptor 
interactions as weak or weaker than the proposed basigin‑spike binding, we report no evidence for 
a direct interaction between the viral spike protein to either of the two common isoforms of basigin. 
Finally, removing basigin from the surface of human lung epithelial cells by CRISPR/Cas9 results in no 
change in their susceptibility to SARS‑CoV‑2 infection. Given the pressing need for clarity on which 
viral targets may lead to promising therapeutics, we present these findings to allow more informed 
decisions about the translational relevance of this putative mechanism in the race to understand and 
treat COVID‑19.
The sudden emergence of SARS-CoV-2 in late 2019 has demanded extensive research be directed to resolve the 
many uncharted aspects of this previously-unknown virus. One essential question is what host factors the virus 
uses to recognize and invade human cells. SARS-CoV-2, as with other members of the coronavirus family, invades 
host cells using the large trimeric spike proteins on its surface. A series of studies published within the first few 
months of the COVID-19 pandemic independently confirmed that the same angiotensin-converting enzyme 
2 (ACE2) receptor that was found to mediate SARS spike binding to human cells also mediates SARS-CoV-2 
binding to human  cells1–3. However, for previous coronaviruses closely related to SARS-CoV-2 including SARS 
and MERS, multiple different host receptors have been described with roles facilitating viral  invasion4–7, making 
it plausible that additional interaction partners for the SARS-CoV-2 spike may remain undiscovered. Among 
the most prominent claims for an alternate SARS-CoV-2 host receptor comes from a report identifying basigin 
(CD147) as a binding partner for the SARS-CoV-2 spike protein with functional significance in viral  invasion8. 
Based on a previously-published indirect interaction between the SARS spike protein and cyclophilin A for 
which basigin appeared to be involved, basigin was subsequently found to directly bind the spike SARS-CoV-2 
spike protein with reasonably high affinity (equilibrium dissociation constant of 185 nM, compared to 5–20 nM 
reported for the similarly high-affinity spike-ACE2  binding2,9). Direct binding between the SARS-CoV-2 spike 
“receptor-binding region” of the S1 domain and basigin was demonstrated in those reports by co-immunopre-
cipitation, surface plasmon resonance, and enzyme-linked immunosorbent assays (ELISAs).
Notably, the original finding that basigin is a possible alternative SARS-CoV-2 receptor has already translated 
into an open-label clinical trial of a humanized therapeutic monoclonal antibody against basigin, meplazumab, 
which reported striking improvements in COVID-19 patients treated with  antibody10. Basigin represents an 
attractive medical target because therapeutic agents have already been developed that target basigin based on 
basigin’s previously-established role as an essential host receptor for invasion of the malaria parasite Plasmodium 
falciparum11,12. The claim that basigin acts as a host receptor for SARS-CoV-2 has already featured in published 
articles discussing the prioritization of  therapeutics13, and has been the subject of published analyses looking at 
basigin expression on the assumption that it serves as a viral entry  factor14–16.
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We sought to validate the interaction between the SARS-CoV-2 spike protein and human basigin after 
observing that the result had not yet been reproduced despite intense interest in the interaction’s proposed 
consequences. Using a variety of sensitive approaches for detecting binding interactions and validated reagents, 
we were unable to find any supporting evidence for a direct interaction of the SARS-CoV-2 spike protein with 
basigin. Consistent with this, we found no functional role for BSG in the infection of a human lung cell line 
with SARS-CoV-2. Based on our findings, we encourage caution in approaches aimed at addressing the current 
pandemic caused by SARS-CoV-2 which are rooted in the assumption that basigin acts as a viral recognition 
receptor without further evidence.
Results
We first investigated whether basigin (BSG) expressed on the surface of human cell lines could bind the spike 
protein of SARS-CoV-2. The previous reports of this interaction had not performed any binding experiments on 
full-length basigin displayed on the surface of  cells8. First, we synthesized constructs to recombinantly express 
the spike protein of SARS-CoV-2. We emulated the published designs of spike constructs previously determined 
to be folded and  functional17. Using a mammalian HEK293 expression system to increase the chances that 
structurally-critical post-translational modifications would be  preserved18, we produced both the full extracel-
lular domain of the spike protein, and the S1 domain of the spike that mediates all known receptor binding 
events (Fig. 1a). When HEK293 cells were transiently transfected with cDNA overexpression plasmids for ACE2, 
the transfected cells became strongly stained by fluorescent tetramers of spike protein in either S1 or full forms 
(Fig. 1b). However, no similar gain of binding was observed with HEK293 cells transfected with BSG cDNA 
(Fig. S1). BSG transfection led to significant upregulation of cell-surface BSG (Welch’s t-test of BSG transfected 
vs mock-transfected cells p = 0.01), yet we also noted that these HEK293 cell lines express BSG at high levels 
even without cDNA overexpression (Fig. 1c). Despite this, spike protein tetramers had no detectable background 
staining of our HEK293 cells without ACE2 in either our experiment or similar experiments reported with 
SARS-CoV-2 and HEK293  cells19–21.
Next, we sought to leverage the high sensitivity of direct biochemical binding assays to determine if these 
methods could detect any traces of basigin binding. We have previously expressed the ectodomain of the basigin 
receptor in a functionally active form and used it to discover pathogen ligands including Plasmodium falciparum 
 RH511,22,23. In a HEK293 human cell line, we expressed recombinant forms of the extracellular domains of both 
the canonical isoform of basigin (BSG) that contains two Ig-like domains and an alternate isoform which con-
tains an additional Ig-like domain (BSG-long) (Fig. 2a). To confirm our recombinant constructs were folded and 
biochemically active, we probed the basigin constructs with three different monoclonal antibodies known to bind 
native basigin at the cell  surface12,24 in enzyme-linked immunosorbent assays (ELISAs). All antibodies specifically 
bound to both of our recombinant basigin isoforms but not a negative control construct of recombinant rat Cd4 
tag (Fig. 2b). The protein epitopes recognized by these antibodies retained their conformation in recombinant 
basigin but less so in basigin that is denatured by heat and reducing agent, with each antibody having between 
twofold to > tenfold reduced immunoreactivity after treatment (Fig. 2c). To determine significance, we fit log-
logistic dose–response models to each protein and antibody combination that had at least two  replicates25, with 
Bonferroni-corrected p-values ranging from 0.02 (BSG and MEM-M6/1) to < 0.0001 (all others) when comparing 
denatured and control curves by F-tests.
With the functionality of our constructs quality-tested, we performed a plate-based binding  assay26 that uses 
the avidity gains of multimerized proteins to detect even highly transient protein–protein  interactions27. The 
SARS-CoV-2 spike proteins and ACE2 gave clear binding signals in both binding orientations as plate-bound 
baits and reporter-linked preys, yet no signals were observed for either BSG isoform against either spike con-
struct (Fig. 3a). By contrast the known interaction between BSG and Plasmodium falciparum RH5 was readily 
detected, as was a control low-affinity interaction between human CD200 and CD200R. Notably, these interac-
tions have similar or even weaker affinity than reported for the BSG-spike  interaction11,28. Finally, in response to 
recent reports of a mutation in the SARS-CoV-2 spike that is rapidly displacing the reference  sequence29,30, we 
also checked whether the D614G variant of the spike could bind BSG; again, we could not detect any interac-
tion (Fig. 3b). In all configurations the signal from BSG binding spike protein was indistinguishable from the 
background of non-interacting protein pairs and significantly below the known interaction pairs (Welch’s t-test 
of ACE2-spike interactions vs BSG-spike interactions p = 0.0002) (Fig. 3c).
While these results strongly suggested that the spike protein of SARS-CoV-2 cannot directly bind basigin as an 
entry receptor, to account for the possibility of basigin acting through less direct routes in vivo, we tested whether 
basigin has any functional role in viral infection of a commonly used lung epithelial cell line (CaLu-3)1,31. We 
transduced Cas9-expressing CaLu-3 cells with single guide (sg) RNAs targeting ACE2, BSG, and, as a negative 
control against a similarly abundant receptor, beta-2-microglobulin (B2M) to decrease cell surface MHC class 
I  expression32. We achieved a strong decrease in cell surface expression of each protein encoded by these genes 
(Fig. S2). We then challenged each cell line with an infectious strain of SARS-CoV-2 across a range of doses, 
measuring which cells the virus entered by staining against the viral nucleocapsid protein (Fig. 4a). Targeting 
of the known ACE2 receptor by CRISPR-Cas9 led to a near-complete loss of infectivity (two-way ANOVA of 
ACE2 infection vs B2M control Bonferroni-corrected p-value < 0.001), despite these cells retaining very high 
expression of BSG (Fig. 4b). In contrast, genetic removal of BSG had no significant effect on infectivity, with 
similarly high rates of viral entry seen compared to the B2M control (two-way ANOVA of BSG infection vs B2M 
infection Bonferroni-corrected p-value > 0.90) and to the parental CaLu-3 cells having no genes knocked out.
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Discussion
Identifying the host receptors which a virus can recognize is an important step in mechanistically explaining 
viral infection, and can offer insight in a virus’ cellular tropism and factors influencing susceptibility. Despite the 
importance of determining precisely which entry receptors SARS-CoV-2 uses to infect human cells, there remains 
considerable uncertainty amid multiple claims of several viral receptors with variable qualities of data to support 
these  assertions8,33–36. We investigated one of the most prominent claims, that human BSG acts as an alternate 
receptor for the virus to interact with, which has been the topic of several studies, news and review articles, and 
a clinical  trial10,14,15,37–42. Our access to established tools and reagents from previous work studying BSG’s role as 
a host receptor in Plasmodium infection allowed us to rapidly investigate BSG as a SARS-CoV-2 receptor. Despite 
validating the functionality of all our reagents, we were unable to detect any binding in biochemical or cell-based 
Figure 1.  Gain of SARS-CoV-2 spike binding activity on human cells over-expressing ACE2 but not BSG. (a) 
Expression and purification of the S1 domain and full ectodomain of the SARS-CoV-2 spike protein produced 
in human cell lines. Two independent preparations of purified spike were resolved by SDS-PAGE under 
reducing conditions and stained with Coomassie blue dye. (b) Cells transfected with cDNAs encoding ACE2 but 
not BSG bind highly avid fluorescent SARS-CoV-2 spike tetramers. Flow cytometry fluorescence distributions 
of cells stained with tetramers composed of biotinylated spike protein either using the S1 domain (top panels) 
or the entire ectodomain (lower panels) clustered around phycoerythrin-conjugated streptavidin. The stained 
HEK293 cells were transfected with cDNA to overexpress either ACE2 (left) or BSG (right). Mock-transfected 
cells are shown in red. Similar behavior to the data shown was observed in three separate tests. (c) Transfection 
with BSG cDNA leads to upregulation of cell-surface BSG. Surface basigin levels on HEK293 cells labeled with 
an anti-human BSG monoclonal antibody. BSG levels are compared to a negative control of secondary-antibody 
only. Mean antibody fluorescence intensities are summarized in the adjacent bar graph, with error bars showing 
standard deviations (n = 2–4).
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assays for either common BSG isoform or either configuration or allele of the SARS-CoV-2 spike protein. Further, 
in viral infection assays with authentic SARS-CoV-2 in lung cell lines, we observed no role of BSG in infection.
BSG is highly expressed on many cell types throughout the body, including activated lymphocytes and red 
blood cells, forming the basis of the Ok blood grouping  system43. Notably, SARS-CoV-2 has not been found to 
enter red blood  cells44. However, the possibility that BSG could act as an accessory binding receptor for the virus 
has been speculated in several publications to possibly explain in part the link between SARS-CoV-2 infection 
and hematological symptoms in  patients39,40,45,46. Our data suggest this hypothesis should be treated cautiously. 
Similarly, if our negative findings are replicated, it would necessitate a re-interpretation of the clinical trial 
involving injections of anti-BSG monoclonal antibodies, as any patient benefit would be more likely explained 
by alternative hypotheses such as immune modulation as opposed to direct blockage of viral invasion through 
BSG. Hypotheses relying on BSG binding to explain viral tropism may also need closer  reconsideration14.
A recent genomic study investigating variants in genes reported to be linked to SARS-CoV-2 infection failed 
to find evidence of BSG variants enriched in COVID-19 patients, despite identifying associations with more 
established viral entry factors such as  TMPRSS247. Combined with our own infection tests in lung cells with BSG 
genetically ablated, we see no evidence supporting a direct role for BSG in viral infection. While our results all 
Figure 2.  Basigin expressed as recombinant protein ectodomains retain their biochemical activity. (a) 
Expression and purification of two and three Ig-like domain isoforms of basigin. Proteins were resolved 
under reducing conditions by SDS-PAGE and stained with a Coomassie dye (b). Recombinant basigin but 
not control proteins are recognized by anti-basigin monoclonal antibodies. ELISA dilution series of BSG and 
BSG-long recognized by three different monoclonal antibodies, and a control OX68 antibody against their 
tags. A negative control of a recombinant Cd4 tag is included for each antibody. (c) Recombinant basigin 
retains folded conformation of epitopes recognized by three different monoclonal antibodies. ELISA dilution 
curves comparing unmodified basigin to protein treated with heat and a reducing agent. Three replicates were 
performed for all ELISA curves except MEM-M6/6, for which only a single trial was done. Dose response curve 




Scientific Reports |          (2021) 11:413  | https://doi.org/10.1038/s41598-020-80464-1
www.nature.com/scientificreports/
Figure 3.  Sensitive assays designed to detect extracellular protein interactions do not detect a direct interaction 
between human basigin and the SARS-CoV-2 spike protein. (a) No signs of spike-basigin binding in an avidity-
based protein interaction assay systematically testing a matrix of recombinant baits immobilized to streptavidin-
coated plates (rows) against preys clustered around HRP-conjugated streptavidin (columns). A photograph 
of a representative assay plate (left) is shown alongside background-corrected absorbance values averaged 
across two replicates. (b) The emerging D614G mutant variant of the SARS-CoV-2 spike also does not bind 
basigin. Binding matrix including the common D614G variant of the SARS-CoV-2 spike protein instead of the 
reference sequence. (c) Spike protein binding to basigin is consistently undetectable compared to other control 
interactions. Binding signals were averaged across bait and prey orientations for known interacting protein 
pairs, the basigin-spike pairs, and all other pairs. Error bars represent standard deviation from the mean (n = 2, 
except “All others” n = 58).
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point to the lack of a direct role for BSG, as mentioned above, BSG could still have some biological relevance 
through indirect  routes48. For example, through its previously-described role in the development of the immune 
system, BSG could indirectly influence COVID-19 clinical  progression49.
Although our findings are negative, they nevertheless carry important potential implications to both our 
understanding of the basic biology of SARS-CoV-2 and efforts to translate knowledge of the virus’ host receptors 
into therapeutics. We encourage greater study in confirming the mechanisms that have been proposed, not just 
for BSG but also for the multiple other putative viral receptors, so as to resolve the uncertainty around whether 
SARS-CoV-2 utilizes any receptors beyond ACE2 during infection.
Materials and methods
Expression construct design. cDNA expression constructs were taken from a previously-assembled 
library of full-length human cDNAs in human expression  vectors50. The BSG construct was cloned from a 
copy (Origene #RG203894) of the canonical 2-domain isoform of BSG (NM_198589.1), while the ACE2 
cDNA (NM_021804.2) was expressed from a similar expression vector utilizing a CMV promoter (Geneocopia 
#EX-U1285-M02). A small amount of MCT4 (NM_001042422.1), which is known to facilitate BSG surface 
 expression51, was co-transfected along with BSG at a 1:4 ratio to achieve significant BSG overexpression. The 
recombinant human BSG ectodomain constructs have been previously  described11,23 and span from M1-L206 
Figure 4.  Knockdown of basigin by CRISPR-Cas9 in a lung cell line has no effect on susceptibility to SARS-
CoV-2 infection. (a) Knockout of the known viral entry receptor ACE2 blocks viral infection in CaLu-3 cells, 
but not single guide (sgRNA) knockouts of basigin or negative control MHC class I receptors. Representative 
flow-cytometry profiles of SARS-CoV-2 nucleocapsid protein in CaLu-3 cells 48 h post-infection. (b) Lung 
cells with cell-surface basigin knocked down have no significant change in rates of viral entry and SARS-CoV-2 
infection. Three replicates were performed of all 3 knockout conditions. Shading represents standard deviation 
from the mean percent of cells infected.
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(BSG) or M1-L322 (BSG-long). The extracellular domain truncations for the SARS-CoV-2 spike proteins have 
also been previously  published17. The S1 domain was defined as spanning Q14-Y647, while the full spike ecto-
main spanned Q14-K1211. The endogenous viral signal peptide was replaced with an efficient mouse antibody 
signal  peptide52. As previously described, the full spike ectodomain was mutated at its polybasic protease cleav-
age site (682-685 RRAR to SGAG), had a proline stabilizing mutation introduced (986–987 kV to PP), and to 
mimic the natural trimerized structure of the spike had a foldon trimerization domain introduced at its C-ter-
minus. The ACE2 ectodomain spanned M1-S740, retaining its endogenous signal peptide.
Recombinant protein expression and purification. Human embryonic kidney (HEK)-293E cells were 
transiently transfected with polyethylenimine as previously  described53,54. Per 100 mL of cells, 50 µg of plas-
mid was transfected along with 1 µg of a plasmid encoding the biotin-ligase BirA to direct biotinylation of the 
recombinant  proteins55. Cells were grown in Freestyle Media (Life Technologies #12338018) supplemented with 
100 µM D-biotin (Sigma #2031). Human proteins were incubated for 120 h at 37 °C, while spike proteins were 
shifted to 34 °C and supplemented with 0.5% (m/v) tryptone N1 (OrganoTechnie #19553) 24 h post-transfection 
and incubated a further 96 h based on a published spike-specific optimized  protocol56. After incubation, cell 
culture supernatants were harvested and passed through 0.22 µm filters. Purification was done using nickel-
nitrilotriacetic acid (Ni-NTA) resins (Thermo Scientific #88221) that were pre-washed for 10 min in 2 washes of 
25 mM imidazole (Sigma #I2399) phosphate buffer. Supernatants were mixed with pre-washed Ni–NTA resin 
overnight at 4 °C, then washed three times with 25 mM imidazole phosphate buffer before eluting in 200 mM 
imidazole buffer. Purified proteins were analyzed on 4–12% gradient Bis–Tris gels (Invitrogen #NP0329) fol-
lowing denaturation for 10 min at 80 °C in NuPAGE sample buffer (Invitrogen #NP0007, #NP0004). Across 
experimental replicates, independent batches of protein were used, with the exception of BSG and BSG-long for 
which a single batch was quality-tested and used in all subsequent experiments.
Flow cytometry and tetramer binding assays. To generate transfected cells overexpressing cell-
surface receptors, human embryonic kidney (HEK)-293E cells were seeded one day prior to transfection at a 
density of 2.5 × 105 cells per mL in Freestyle Media (Life Technologies #12338018) supplemented with 10% heat-
inactivated fetal bovine serum (FBS). Cells were transiently transfected with polyethylenimine as previously 
 described4,22, except with double the ratio of DNA to cells. Then 48 h after transfection, cells had culture media 
aspirated and were resuspended in 1 μM DAPI (Biolegend #422801) and incubated on ice for 5 min. Cells were 
then stained in u-bottom 96-well plates (Greiner #650161) with recombinant protein tetramers conjugated to 
phycoerythrin (PE). Tetramers were prepared by mixing 1 or 5 pmol of biotinylated protein monomer with 0.25 
to 1.25 pmol of streptavidin-PE (Biolegend #405245) respectively and incubating for 2 h at room temperature. 
Cells were spun down and resuspended in 100 μL of tetramer in a solution of 1% bovine serum albumin (BSA) 
and phosphate buffered-saline (PBS) supplemented with calcium and magnesium ions (Gibco #14040133). Cells 
and tetramers were incubated on ice for 45 min, washed in cold PBS, and finally resuspended in the same 1% 
BSA PBS solution. Antibody staining was performed with a similar procedure, except during the first 30 min 
on ice cells were incubated with 30 μg/mL of monoclonal Ab-1 anti-BSG  antibody12, then resuspended in 1:500 
anti-human IgG antibody conjugated to Cy3 (Sigma #C2571). Fluorescence staining was measured by a BD 
Fortessa flow cytometer.
Monoclonal antibody ELISAs. Streptavidin-coated 96-well plates (Nunc #436014) were pre-washed in 
175 μL hepes-buffered saline (HBS) with 0.1% tween-20 (HBS-T), then blocked in 2% (m/v) bovine serum albu-
min (BSA, Sigma #A9647) in HBS for 1 h at room temperature. In a separate 96-well plate, a 1:4 dilution series 
of biotinylated BSG or control protein was prepared in 2% BSA HBS, then 100 μL of the protein dilution trans-
ferred to the blocked streptavidin-coated 96-well plate. In the experiments to determine the protein’s sensitivity 
to heat and reduction treatment, one half of the protein sample was denatured by heating at 80 °C for 10 min 
in the presence of 5% beta-mercaptoethanol. After capturing protein for 1 h at room temperature, plates were 
washed three times with 150 μL HSB-T. Anti-human basigin monoclonal antibodies were added at the follow-
ing concentrations: 1.7 μg/mL Ab-1 (Zenonos et al., formerly known as ch6D9, recognizing the IgC2 domain)12, 
2.2 μg/mL MEM-M6/1 (Abcam #ab666), and 1.3 μg/mL MEM-M6/6 (Abcam #ab119114)24. A control mouse 
anti-rat Cd4 domain 3 + 4 monoclonal antibody (OX68) against the tags of our recombinant proteins was used 
at a 1.6  μg/mL concentration. After 1  h of incubation with the primary antibody and three HBS-T washes, 
secondary antibody was added as 1:7000 donkey anti-human IgG (Abcam #ab102407) for ch6D9 and for all 
other antibodies as 1:3500 goat anti-mouse IgG (Sigma #A9316). Both secondary antibodies were conjugated 
to alkaline phosphatase. After 45 min of incubation with the secondary antibody, the plates were washed again 
three times with HBS-T. A substrate of 60 μL 2 mg/mL para-Nitrophenylphosphate (Sigma #P4744) in dietha-
nolamine buffer was added to each well to develop signal over 30 min. Absorbance was measured on a Tecan 
plate reader at 405 nm.
Avidity‑based binding assays. Biotinylated recombinant proteins were tetramerized around streptavi-
din-HRP (Pierce #21130) for 1 h at room temperature to form reporter-linked preys. Per well of the assay plate, 
0.1 pmol of recombinant monomer were added to 0.025 pmol of streptavidin to create a highly avid binding 
reagent. Streptavidin-coated 96-well plates (Nunc #436014) were pre-washed in 175 μL hepes-buffered saline 
(HBS) with 0.1% tween-20 (HBS-T), then blocked in 2% (m/v) bovine serum albumin (BSA, Sigma #A9647) in 
HBS for 1 h at room temperature. Biotinylated baits were captured by adding 0.1 pmol of purified protein diluted 
in 2% BSA to each well of the plate. After incubating the baits for 2 h at 4 °C, plates were washed three times 
with 150 μL HBS-T. The pre-formed tetrameric preys were then added and the plate incubated for 1 h at room 
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temperature. The plate was finally washed twice in 150 μL HBS-T and once in 150 μL HBS before adding 60 μL 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Sigma #T0440). After developing signal for 15 min at room 
temperature, the reaction was halted by the addition of 0.25 M HCl. Absorbance was measured on a Tecan plate 
reader at 405 nm.
CaLu‑3 genome editing and validation. CaLu-3 cells were cultured in Minimum Essential Media 
(MEM) with 10% FCS, 1 mM sodium pyruvate, MEM non-essential amino acids and GlutaMAX. CaLu-3 were 
transduced with lentivirus containing FLAG-NLS-Cas9 cloned into pHRSIN.pSFFV MCS(+) pSV40-Blast vec-
tor, and selected with blasticidin at a concentration of 10 µg/mL. Single-guide RNAs (sgRNAs) against ACE2 and 
B2M were cloned into pKLV.U6-gRNA-pGK-Puro-P2A-BFP vector (Addgene #50946). sgRNA lentiviruses were 
transduced into CaLu-Cas9 cells and selected with puromycin at a concentration of 2 µg/mL. Following puromy-
cin selection of sgRNA expressing CaLu-Cas9, ~ 5 × 106 trypsinized cells were harvested for cell-surface staining. 
Cells were pelleted and resuspended in a solution of 5% FCS in PBS with either 3.75 pmol full spike ectodomain 
tetramer conjugated to AF647, or a mixture of 1  µg/mL anti-MHC-I mouse monoclonal antibody (W6/32) 
and anti-BSG human monoclonal antibody (Ab-1) and incubated on ice for 1 h. Cells stained with primary 
antibodies were washed and stained on ice with goat anti-mouse conjugated to Alexa Fluor-568 (Thermo Fisher 
#A11031) and goat anti-human conjugated to Alexa Fluor-647 (Thermo Fisher #A21445) secondary antibodies 
at a dilution of 1:2000 for 30 min. Cells were washed and resuspended in FCS PBS solution prior to analysis on 
a BD Fortessa flow cytometer.
SARS‑CoV‑2 infection assays. The SARS-CoV-2 virus used in this study is the clinical isolate named 
"SARS-CoV-2/human/Liverpool/REMRQ0001/2020"31,57. In total, the stock used was passaged three times in 
VeroE6 cells, once in CaCo-2 cells and once in CaLu-3 cells. Viral titre was determined by 50% tissue culture 
infectious dose  (TCID50) in Huh7-ACE2 cells. For viral infection assays 5 × 10
4 CaLu-3 cells were plated per well 
of a 24-well tissue culture dish 72 h prior to addition of SARS-CoV-2 virus at the indicated MOI. At 48 h post-
infection cells were washed with PBS, dissociated with TrypLE, and fixed in 4% formaldehyde for 15 min. Fixed 
cells were washed and incubated for 15 min at room temperature in Perm/Wash buffer (BD #554723). Permea-
bilized cells were pelleted, stained for 15 min at room temperature in 100 µL of sheep anti-SARS-CoV-2 nucle-
ocapsid antibody (MRC-PPU, DA114) at a concentration of 0.7 µg/mL, washed and incubated in 100 µL AF488 
donkey anti-sheep (Jackson ImmunoResearch #713-545-147) at a concentration of 2 µg/mL for 15 min at room 
temperature. Stained cells were pelleted and fluorescence staining analysed on a BD Fortessa flow cytometer.
Data processing. For flow cytometry experiments, measurement events for analysis were gated on live 
singlet cells (based on DAPI and forward and side scatter profiles) using FlowJo version 9. No compensation 
was done because only a single fluorochrome was used for cell staining. Cytometry data was visualized using 
the CytoML  package58 in R version 3.6.1. For plate-based experiments, raw absorbance values had background 
subtracted. Background for ELISAs was defined as the minimum absorbance of any well on the measured plate, 
and background for binding assays was defined as the median absorbance of each respective tetrameric prey. For 
better comparisons across replicates, these corrected absorbances were rescaled by min–max normalization so 
that the maximum absorbance on that replicate’s entire plate is defined as 1. Statistics on binding assay data were 
calculated using the t.test function in the R base stats package (version 3.6.1). Two-way ANOVAs on viral infec-
tion data were likewise done in R with the aov function for an additive model of viral nucleocapsid-positive cells 
from viral dose and knockout condition. Statistics on ELISA data were calculated by performing an F-test com-
paring a two-parameter log-logistic dose response model fitted to the ELISA data to a null model where both the 
denatured and control protein conditions were assumed to be identical. Model fitting and statistical procedures 
were done using the drc package in R as previously  described25. Data is available upon request.
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